Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
The antibody was designed and developed at Abzena’s Cambridge, UK,
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery
Merck opens first climate-neutral manufacturing facility in Ireland
Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Subscribe To Our Newsletter & Stay Updated
